Elritercept vs. Epoetin Alfa: High-Bar Phase III Design Enters Crowded MDS Arena With Mechanism Unknown

King's Recruits First Global Patient for Takeda's Phase III MDS Trial

King's College Hospital NHS Foundation Trust has announced the recruitment of the first global patient for Takeda Pharmaceuticals' Phase III trial, TAK-226-3001. This study evaluates elritercept against epoetin alfa for treating anaemia in adults with very low, low, or intermediate risk myelodysplastic syndromes (MDS) who require regular red blood transfusions. The trial aims to enroll 300 participants, who may remain in the study for up to five years, with primary objectives focused on reducing red blood cell transfusions and assessing safety.

• The TAK-226-3001 Phase III trial is designed to compare the efficacy and safety of elritercept against epoetin alfa. Its primary goal is to determine if elritercept can reduce the need for red blood cell transfusions in eligible MDS patients. Secondary objectives include evaluating patient-reported fatigue, overall transfusion burden, quality of life, and the immune response to the investigational therapy.
• The study targets adults diagnosed with very low, low, or intermediate risk myelodysplastic syndromes, a pre-leukaemic disorder characterized by a high risk of progression to leukaemia and common development of anaemia requiring transfusions. These patients currently rely on supportive erythropoietin injections, which, if ineffective, lead to regular blood transfusions.
• King's College Hospital, a National Reference Centre for MDS and one of only two UK hospitals participating, successfully recruited the first global patient for this significant trial. This achievement, supported by the NIHR Clinical Research Facility, aligns with national targets to accelerate clinical trial setup in the UK and offers a crucial opportunity for MDS patients to access potentially transformative therapy.

Unpacking the TAK-226-3001 Trial Design for MDS Anaemia

Several key randomized and single-arm trials have evaluated therapeutic interventions in myelodysplastic syndromes (MDS), spanning transfusion independence, hematologic response, and survival outcomes. The trials below reflect a range of study designs, patient populations, and endpoint structures relevant to the MDS treatment landscape.

Addressing Unmet Needs in Lower-Risk MDS-Related Anaemia

Current treatment approaches for myelodysplastic syndromes (MDS) face substantial limitations across both lower-risk and higher-risk disease settings. Despite a growing therapeutic armamentarium, durable responses remain elusive and significant clinical gaps persist across the patient population.

• ESA resistance and transfusion burden in lower-risk MDS: Erythropoiesis-stimulating agents (ESAs) are the standard first-line therapy for anemia in low-risk MDS (LR-MDS), yet high rates of primary resistance are well documented, and most patients either do not respond or eventually develop resistance. Chronic red blood cell transfusions, used to alleviate anemia symptoms, carry risks of iron overload and decreased quality of life without addressing the underlying disease.

• Limited durability of available salvage options in LR-MDS: Agents such as lenalidomide, hypomethylating agents (HMAs), and immunosuppressive therapy can provide hematologic responses in selected patient subsets following ESA failure, but durable responses are limited and these agents can carry significant adverse effects. Luspatercept, approved for LR-MDS with ring sideroblasts refractory to ESA, demonstrated improvement in transfusion independence with a well-tolerated safety profile, but its benefit is confined to a specific phenotypic subgroup.

• Management of non-anemic cytopenias: While anemia is the most common cytopenia in LR-MDS, thrombocytopenia and neutropenia management is challenging, and the co-occurrence of these cytopenias with anemia may dictate the choice of therapy — further complicating treatment decisions.

• HMA failure in higher-risk MDS carries a dismal prognosis: Azacitidine and decitabine are the standard of care for frontline treatment of higher-risk MDS, yet complete responses are rare and typically not durable, with a median response duration of 11–15 months and only 10–20% of patients experiencing complete hematologic and cytogenetic response. Once an HMA fails, median survival is less than 6 months unless the patient undergoes hematopoietic stem cell transplantation (HSCT). Salvage therapies — including novel HMAs and CTLA-4/PD1-type immune checkpoint inhibitors — have yielded "mixed and only modest results at best."

• Restricted access to curative transplantation, particularly in elderly patients: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only potentially curative treatment for MDS, yet it is frequently inaccessible to elderly patients due to advanced age, comorbidities, poor performance status, or lack of a human leukocyte antigen-identical donor. As the median age at MDS diagnosis falls in the seventh decade, this limitation affects a substantial proportion of the patient population.

• Adverse mutational profiles further constrain outcomes: Somatic mutations in genes such as TP53, ASXL1, RUNX1, and EZH2 are associated with adverse clinical features and inferior outcomes. TP53 mutations in particular drive intrinsic resistance to conventional cytotoxic therapies and are associated with a high risk of relapse after allogeneic transplantation. The biology of HMA failure remains poorly defined, which significantly limits rational drug development in this setting.

Elritercept's Potential Against Current MDS Anaemia Treatments

Published studies evaluating standard-of-care (SOC) treatments for myelodysplastic syndromes (MDS) reveal a complex efficacy landscape across risk strata. Hypomethylating agents (HMAs) — azacitidine and decitabine — represent the most widely used interventions, particularly in higher-risk disease. A systematic review of randomised controlled trials reported overall survival rates of 33.2% versus 21.4% for HMA versus conventional care regimens (CCR), respectively (RR 0.83, 95% CI 0.71–0.98), with overall response rates of 23.7% versus 13.4% (RR 0.87, 95% CI 0.81–0.93). Subgroup analyses indicated that only azacitidine demonstrated an OS improvement (RR 0.75, 95% CI 0.64–0.98), while decitabine did not. In a real-world SEER-Medicare analysis of 3,046 HMA-treated patients, median survival was 11.6 months for the higher-risk group and 18.4 months for the intermediate-risk group, with median time-to-AML transformation of 19.3 months and 50.4 months, respectively — underscoring the persistent unmet need in this population.

In lower-risk MDS, the evidence for HMAs and lenalidomide as second-line options following erythropoiesis-stimulating agent (ESA) failure is notably limited. A large international retrospective cohort of 1,698 non-del(5q) lower-risk MDS patients treated with ESAs showed an erythroid response rate of 61.5% and a median response duration of 17 months. Among the 450 patients who received second-line treatment, five-year OS for those receiving HMAs, lenalidomide, and other treatments was 36.5%, 41.7%, and 51%, respectively (P = .21), with no significant OS difference identified in multivariable analysis. A separate retrospective study from Nagasaki similarly found no significant survival benefit of azacitidine for lower-risk MDS patients, with median OS of 29 months for azacitidine-treated patients versus 91 months for those receiving ESAs and not reached for immunosuppressive therapy. In non-del(5q) lower-risk MDS patients refractory to ESAs, lenalidomide yielded an erythroid response in 48% of patients, with 37% of previously transfusion-dependent patients achieving transfusion independence and a median response duration of 24 months.

Oral azacitidine (CC-486) has been evaluated as an extended-dosing investigational formulation in patients with MDS, chronic myelomonocytic leukemia, and AML. In a clinical study using CC-486 300 mg once-daily for 21 days of repeated 28-day cycles, the overall response rate in the MDS/CMML subgroup was 32%, with red blood cell transfusion independence achieved in 33% of patients. The most common grade 3–4 treatment-emergent adverse events were neutropenia (42%) and anemia (29%), a safety profile described as comparable to that of injectable azacitidine. Additionally, a prospective study of ruxolitinib and decitabine combined with a modified busulfan-cyclophosphamide conditioning regimen in high-risk AML/MDS patients undergoing allogeneic hematopoietic stem cell transplantation reported a 2-year cumulative incidence of relapse of 19.0%, with 2-year OS and disease-free survival probabilities of 70.3% and 70.6%, respectively, suggesting tolerability and reduced relapse in this high-risk setting.

Elritercept's Pivotal Bid to Reshape First-Line MDS Anemia Care

The launch of Takeda's Phase III trial for elritercept marks a pivotal moment in the evolving treatment landscape for anemia in lower-risk myelodysplastic syndromes (MDS). For patients grappling with the chronic burden of red blood cell (RBC) transfusions, current erythropoiesis-stimulating agents (ESAs) like epoetin alfa, while effective for some, often provide limited or transient responses. This leaves a significant unmet need for more durable solutions.

Elritercept, a TGF-β ligand trap, represents a promising therapeutic class that targets the underlying ineffective erythropoiesis in MDS. Its direct comparison against epoetin alfa in ESA-naive patients signals Takeda's ambition to establish elritercept as a new first-line option. This strategy is bolstered by the recent success of luspatercept, another TGF-β ligand trap, which has already demonstrated superior transfusion independence rates compared to epoetin alfa in a similar patient population. This sets a high bar for elritercept, requiring it to not only match but ideally surpass these efficacy benchmarks.

However, the path forward is not without challenges. The competitive landscape is intensifying with the approval of luspatercept and imetelstat, alongside established ESAs and hypomethylating agents. Elritercept's safety profile will be under scrutiny, particularly concerning potential grade 3/4 adverse events such as hypertension, dyspnea, and cytopenias, which have been observed with similar agents. Furthermore, demonstrating consistent efficacy across diverse patient subgroups, including those with varying endogenous erythropoietin levels or ring sideroblast status, will be crucial for broad clinical adoption. The trial's extended duration, up to five years, underscores a commitment to evaluating long-term durability and safety, which are paramount for a chronic condition like MDS. A successful outcome could significantly reduce transfusion dependence, improve patient quality of life, and fundamentally reshape the initial therapeutic approach for lower-risk MDS anemia.